Olink Proteomics AB.png
Olink® Introduces Global Network of Certified Service Providers to Accelerate Protein Biomarker Discovery
July 03, 2024 08:00 ET | Olink Proteomics AB
Inaugural network of Olink® Certified Service Providers includes eading contract research organizations (CROs) and service labs around the world.
Olink Proteomics AB.png
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
May 30, 2024 08:00 ET | Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
DMR Logo.png
3D Cell Culture Market is expected to reach revenue of USD 5.0 Bn by 2032, at 12.0% CAGR: Insights by Dimension Market Research
April 23, 2024 11:25 ET | Dimension Market Research
New Jersey, New York, Los Angeles, Austin, San Diego, Philadelphia, Phoenix, April 23, 2024 (GLOBE NEWSWIRE) -- Overview The 3D Cell Culture Market size was valued at USD 1.8 billion in 2023 and is...
Olink Proteomics AB.png
Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
April 02, 2024 08:00 ET | Olink Proteomics AB
Olink delivers new open access data library consisting of over 300,000 protein-disease risk associations across 106 human diseases.
Olink Proteomics AB.png
Landmark studies utilizing Olink® Explore technology signal a new era for population-scale proteogenomics
October 05, 2023 16:25 ET | Olink Proteomics AB
Three landmark studies published in Nature demonstrate the power of Olink technology for understanding human biology.
GDX_Logos_Blue_211220_01_600x208.jpg
GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”
March 20, 2023 08:45 ET | GeneDx Holdings Corp.
Genome Sequencing and Interpretation Services Progressing Quickly for 1,000 Newborns Enrolled in Study to Date; On Track to Support up to 100,000 Study Participants in Next Four YearsInitial Data and...
Sema4_Logo2021_Primary_Gradient.png
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
April 05, 2022 08:00 ET | Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
March 14, 2022 16:05 ET | Sema4
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue...
Sema4_Logo2021_Primary_Gradient.png
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
March 08, 2022 08:00 ET | Sema4
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company’s prestigious annual...
Sema4_Logo2021_Primary_Gradient.png
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
February 22, 2022 16:05 ET | Sema4
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...